Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

The modestly efficacious HIV-1 vaccine regimen (RV144) conferred 31% vaccine efficacy at 3 years following the four-shot immunization series, coupled with rapid waning of putative immune correlates of decreased infection risk. New strategies to increase magnitude and durability of protective immunit...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, Siriwat Akapirat, Lindsay C Dahora, Matthew Zirui Tay, Sherry Stanfield-Oakley, Saintedym Wills, Derrick Goodman, DeAnna Tenney, Rachel L Spreng, Lu Zhang, Nicole L Yates, David C Montefiori, Michael A Eller, David Easterhoff, Thomas J Hope, Supachai Rerks-Ngarm, Punnee Pittisuttithum, Sorachai Nitayaphan, Jean-Louis Excler, Jerome H Kim, Nelson L Michael, Merlin L Robb, Robert J O'Connell, Nicos Karasavvas, Sandhya Vasan, Guido Ferrari, Georgia D Tomaras, RV305 study team
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Public Library of Science (PLoS) 2023-05-01
Seri Bilgileri:	PLoS Pathogens
Online Erişim:	https://doi.org/10.1371/journal.ppat.1011359
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

Benzer Materyaller